GSK PLC closed 23.31% below its 52-week high of £18.24, which the company reached on May 16th.

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Blue Trust Inc. lifted its position in GSK plc (NYSE:GSK – Free Report) by 16.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,505 shares of the pharmaceutical ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

GSK plc and the University of Oxford (Oxford) announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer ...

Learn More. If the GSK (LSE: GSK) share price was a video game, it would be flashing GAME OVER to me right now. Shares in the pharmaceutical giant started 2025 trading at a 12-month low.